Treat-to-target of Gouty Arthritis at Rak-Kor Clinic Nongkhai Hospital
Keywords:gout, hyperuricemia, treat-to-target
Background: Gout is the most common inflammatory arthritis worldwide. In the past 20-30 years, there has been a tendency to find more patients worldwide. As in Asia, where the number of cases is rapidly increasing in China, Thailand, South Korea, and Taiwan, there are still many problems in terms of diagnosis and treatment. Objective: To determine the factors related to the targeted treatment of gouty arthritis which uric acid levels were less than 5.0 mg/dL in patients with tophi and less than 5.5 mg/dl in patients without tophi. Methods: The present study method was descriptive by collecting retrospective data of patients with gouty arthritis, ICD 10 M100-109 code, who received treatment at Rak-Kor Clinic, Nongkhai Hospital between 1st July 2010 and 31st December 2020. The factors involved in the treat-to-target of gouty arthritis were analyzed by chi-square test or Fisher’s exact test, and multiple logistic regression (95% CI, p<0.05). Results: Of eligible 585 patients, 94.0% and 90.4% of patients achieved the target uric acid level at one year and throughout the treatment period, respectively. The factors associated with achieving treat-to-target for gouty arthritis with the first 1-year were glomerular filtration rate before treatment ≥ 60 ml/min/1.73 m2 (p=0.024, adjusted OR 2.548, 95% CI 1.133, 5.726) and no drug discontinuation (p=0.011, adjusted OR 2.652, 95% CI 1.245, 5.649). The factors associated with achieving treat-to-target for gouty arthritis throughout the treatment period were body mass index ≤ 25 kg/m2 (p=0.012, adjusted OR 0.355, 95% CI 0.158, 0.797), absence of tophi (p=0.022, adjusted OR 2.172, 95% CI 1.120, 4.211), glomerular filtration rate before treatment ≥ 60 ml/min/1.73 m2 (p=0.001, adjusted OR 3.493, 95% CI 1.639, 7.447), and no drug discontinuation (p=0.039, adjusted OR 2.056, 95% CI 1.037, 4.079). Conclusion: Assessment of the presence of tophi, body mass index, glomerular filtration rate before treatment, and the patient’s regular medication intake will help in planning the treatment and increasing the patient’s target uric acid level.
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020 Jul;16(7):380-90.
Richette P, Bardin T. Gout. Lancet. 2010 Jan 23;375(9711):318-28.
Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021 May 15;397(10287):1843-55.
Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009 May; 48 Suppl 2: ii2-ii8.
Pascart T, Lioté F. Gout: state of the art after a decade of developments. Rheumatology 2019; 58:27-44.
Deesomchoke U. Management of patients with joint diseases and rheumatism. Revised ed: Faculty of Medicine, Chulalongkorn University;2005.
Rose S, Daniel TA. Mary BB. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. Expert Opin Pharmacother 2017 Aug; 18(11):1115-25.
Saraswate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006 Jul; 81(7):925-34.
Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007 Jun 15;57(5):822-9.
Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) Jan; 49(1):105-11.
Chetanananda N. Drug Utilization review in patients with gouty arthritis at Takuatung Hospital. Med J Reg 11 2016;30: 115-28.
Hanvivadhanakul P, Wongdet R. Outcome of Treatment in Gouty Arthritis Patients: A Retrospective Study. J Med Assoc Thai. 2015 Apr;98 Suppl 3: S46-50.
Mangkala J. Retrospective Study on Diagnosis and Treatment of Gouty Arthritis Patients at Outpatient Department, Nongkhai Hospital during the past 1 year. Udonthani Hospital Journal. 2010 Sep-Dec; 18(3):247-55.
Mangkala J. Retrospective Study on Treatment of Gouty Arthritis Patients at Rak-Kor clinic, Nong Khai Hospital. Buddha- sothorn Hospital Journal. 2015 Oct-Dec; 31(4):63-72.
FitzGerald JD, Dalbeth N, Mikuls T, Petersen RB, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-60.
Quilisadio JEC, Salido EO, Penserga EG. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines. Mod Rheumatol. 2021 May;31(3):755-61.
Perez-Ruiz F, Dalbeth N. Combination urate-lowering therapy in the treatment of gout: What is the evidence? Semin Arthritis Rheum. 2019 Feb;48(4):658-68.
Richette P, Ruiz FP, Doherty M, Jansen TL, Nuki G, Pascual E, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat. Rev. Rheumatol 2014; 10:654-61.
Son CN, Stewart S, Su I, Mihov B, Gamble G, Dalbeth N. Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis. Semin Arthritis Rheum. 2021 Apr 25;51(4):677-84.
Janssen CA, Oude Voshaar MAH, Klooster PMT, Vonkeman HE, Laar MAFJ. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare Clin Rheumatol. 2019 Aug;38(8):2233-9.
Liang N, Sun M, Sun R, Xu T, Cui L, Wang C, et al. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Ther. 2019 Sep 2;21(1):200.
Corbett EJM, Pentony P, McGill NW. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice Int J Rheum Dis. 2017 Jul;20(7):894-7.
Singh JA, Yang S, Saag KG. Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in the national Veterans Administration gout cohort. J Rheumatol. 2020 Mar;47(3):449-60.
Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, et al. Modifiable Factors Associated with Allopurinol Adherence and Outcomes Among Gout Patients in an Integrated Healthcare System. J Rheumatol. 2015 Mar;42(3):504-12.
How to Cite
Copyright (c) 2022 Department of Medical Services, Ministry of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ข้อความและข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการหรือของวารสารกรมการแพทย์